Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|January 15, 2002

BioPharm International

  • BioPharm International-01-01-2002
  • Volume 15
  • Issue 1

Statistics for Laboratory Method Comparison Studies

by Robert T. Magari, Beckman Coulter Corporation In laboratory testing, you may want to use a new analytical method for measuring a chemical substance. To do so, you must be able to prove that the new method gives the same results as the previous one. Not all statistical methods for making laboratory comparisons are equally valid.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 25 years ago

Outsourcing Outlook: E-Sourcing, Internet Facilitates Flexible Collaboration

almost 25 years ago

Inside Washington: Biotechnology in the Limelight, the Year Ahead

almost 25 years ago

Your Vested Interests: The War of the West

almost 25 years ago

From the Editor: Farewell to 2001 . . . Our Biotech Odyssey Continues

almost 25 years ago

Systematic Troubleshooting for LC/MS/MS: Part 2, Large-Scale LC/MS/MS and Automation

almost 25 years ago

Liposomes (a Review): Part Two, Drug Delivery Systems

almost 25 years ago

Information Age Audits

almost 26 years ago

Considerations During Development of a Protein A-Based Antibody Purification Process

Related to this article

View more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more